Recombinant Human Siglec-2/CD22 Fc Chimera Protein, CF | R&D Systems 1968-SL-050 product information

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human Siglec-2/CD22 Fc Chimera Protein, CF

catalog :

1968-SL-050

quantity :

50 ug

price :

400 USD

more info or order :

R&D Systems product webpage

citations: 8

Reference
Casey N, Klee C, F xe5 ne A, Caulier B, Graczyk Jarzynka A, Krawczyk M, et al. Efficient chimeric antigen receptor targeting of a central epitope of CD22. J Biol Chem. 2023;299:104883 pubmed publisher
Dai X, Park J, Du Y, Na Z, Lam S, Chow R, et al. Massively parallel knock-in engineering of human T cells. Nat Biotechnol. 2023;41:1239-1255 pubmed publisher
Singh N, Frey N, Engels B, Barrett D, Shestova O, Ravikumar P, et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med. 2021;27:842-850 pubmed publisher
Terävä J, Tiainen L, Lamminmaki U, Kellokumpu Lehtinen P, Pettersson K, Gidwani K. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma. PLoS ONE. 2019;14:e0219480 pubmed publisher
Fry T, Shah N, Orentas R, Stetler Stevenson M, Yuan C, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20-28 pubmed publisher
Chen G, Brown N, Wu W, Khedri Z, Yu H, Chen X, et al. Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1. elife. 2014;3:e04066 pubmed publisher
Haso W, Lee D, Shah N, Stetler Stevenson M, Yuan C, Pastan I, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121:1165-74 pubmed publisher
Kwong K, Baskar S, Zhang H, Mackall C, Rader C. Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. J Mol Biol. 2008;384:1143-56 pubmed publisher

product information

brand :

R&D Systems

master code :

1968-SL

SKU :

1968-SL-050

product name :

Recombinant Human Siglec-2/CD22 Fc Chimera Protein, CF

unit size :

50 ug

seo description :

The Recombinant Human Siglec-2/CD22 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human Siglec-2/CD22 Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.

target :

Siglec-2/CD22

category :

Proteins and Enzymes

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS.

conjugate :

Unconjugated

dilution :

Bioactivity

purity :

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.

species :

Human

observed molecular weight :

122-127 kDa, reducing conditions

theoretical molecular weight :

101.9 kDa (monomer)

gene symbol :

CD22

details of functionality :

Measured by the ability of the immobilized protein to support the adhesion of human red blood cells. Kelm, S. et al . (1994) Current Biology 4 :965. The ED50 for this effect is 0.03-0.15 ╡g/mL.

endotoxin note :

<1.0 EU per 1 ╡g of the protein by the LAL method.

accessionNumbers :

CAA42006

applications :

Bioactivity

source :

NS0-derived Recombinant Human Siglec-2/CD22 Fc Chimera Protein, CF

USD :

400 USD

alt names :

B-cell receptor CD22, BL-CAM, B-lymphocyte cell adhesion molecule, CD22, CD22 antigenMGC130020, CD22 molecule, sialic acid binding Ig-like lectin 2, Sialic acid-binding Ig-like lectin 2, Siglec2, SIGLEC-2, SIGLEC2FLJ22814, T-cell surface antigen Leu-14

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage